Innate Pharma (IPHA)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
Fundamental grade
Five factors scored 1 to 9 from IPHA's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Results from SEC filings
Fiscal years, from Innate Pharma's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $25M | $58M | $62M | $20M | $9M |
| Net income | -$53M | -$58M | -$8M | -$49M | -$49M |
| Free cash flow | -$60M | -$20M | -$35M | -$7M | -$53M |
| EPS (diluted) | -$0.66 | -$0.73 | -$0.09 | -$0.61 | -$0.55 |
| Operating margin | -193.6% | -99.6% | -20.6% | -256.3% | -599.8% |
Superinvestors who own IPHA
From each investor's latest 13F filing (what a 13F shows).
Insider buying
Open-market purchases by Innate Pharma's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when IPHA trades at or below it.
New accounts get 7 days of Pro, price alerts included. No card needed.
In the full deep dive
Questions
Are Innate Pharma insiders buying the stock?
No open-market insider purchases of IPHA in the last 12 months, according to SEC Form 4 filings.
Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.